tiprankstipranks
Advertisement
Advertisement
Apogee Therapeutics moved to No Rating at BofA
PremiumThe FlyApogee Therapeutics moved to No Rating at BofA
18d ago
Apogee Therapeutics downgraded to Neutral from Buy at Citi
Premium
The Fly
Apogee Therapeutics downgraded to Neutral from Buy at Citi
18d ago
AbbVie price target raised to $273 from $265 at Canaccord
Premium
The Fly
AbbVie price target raised to $273 from $265 at Canaccord
18d ago
Apogee Therapeutics downgraded to Hold from Buy at Craig-Hallum
PremiumThe FlyApogee Therapeutics downgraded to Hold from Buy at Craig-Hallum
19d ago
Apogee Therapeutics downgraded to Neutral from Outperform at Wedbush
Premium
The Fly
Apogee Therapeutics downgraded to Neutral from Outperform at Wedbush
19d ago
Apogee Therapeutics rises 46.7%
Premium
The Fly
Apogee Therapeutics rises 46.7%
19d ago
Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital
PremiumThe FlyApogee acquisition is ‘net negative’ for Regeneron, says RBC Capital
19d ago
Apogee, Paragon Partner on IL-31R Antibody Program
Premium
Company Announcements
Apogee, Paragon Partner on IL-31R Antibody Program
19d ago
Edward Nash Maintains Buy on Apogee, Reiterates $130 Price Target Amid Potential $10.9B AbbVie All-Cash Acquisition
Premium
Ratings
Edward Nash Maintains Buy on Apogee, Reiterates $130 Price Target Amid Potential $10.9B AbbVie All-Cash Acquisition
19d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100